CD74 Antibody

What is CD74 and where is it primarily expressed in human tissues?

CD74, also known as the MHC Class II-associated invariant chain, is a 33-43 kDa nonpolymorphic type II membrane protein that plays a crucial role in antigen presentation . CD74 is highly expressed on B cells and subsets of activated T cells, Langerhans cells, dendritic cells, and epithelial cells . Monocytes and macrophages also express CD74, though at comparatively lower levels . This differential expression pattern makes CD74 an important marker for distinguishing between immune cell populations.

The expression of CD74 is not limited to normal immune cells but extends to various malignancies. Studies examining CD74 expression in B-cell non-Hodgkin lymphomas found that CD74 is expressed in 100% of diffuse large B-cell lymphoma (DLBCL) samples, 100% of follicular lymphoma (FL) samples, and 94% of mantle cell lymphoma (MCL) samples . Furthermore, high expression levels (>70% of cells) were observed in 86% of DLBCL, 79% of FL, and 63% of MCL samples .

How does CD74 expression differ between naïve and memory B cells?

Flow cytometric analysis has revealed distinct expression patterns of CD74 on different B-cell subpopulations. Although CD74 is expressed on almost all peripheral blood B cells (98.3% ± 1.2% of CD27- naïve B cells and 97.0% ± 2.4% of CD27+ memory B cells), the expression density varies significantly . Memory B cells (CD27+) consistently show higher expression levels of CD74 compared to naïve B cells (CD27-), with an average 1.3-fold increase in mean fluorescence intensity (MFI) . This differential expression pattern suggests distinct functional roles of CD74 in these B-cell subpopulations.

Additionally, the co-receptor of CD74, CD44, shows similar variation in expression patterns. CD44 is expressed on 96.7% ± 2.0% of CD27- naïve B cells and 99.3% ± 0.9% of CD27+ memory B cells, with CD27+ memory B cells showing approximately twofold higher expression density compared to CD27- naïve B cells . These differences in expression patterns provide important considerations for researchers investigating B-cell biology and targeting these populations with CD74 antibodies.

What functions does CD74 perform beyond MHC class II chaperoning?

While CD74 is primarily known as a chaperone for MHC Class II (HLA-DR) proteins, facilitating their translocation from the endoplasmic reticulum to endocytic compartments during antigen presentation, it serves multiple additional functions . CD74 activation through interaction with CD44 and binding to macrophage migration-inhibitory factor (MIF) leads to activation of NFkB and ERK signaling pathways . This signaling cascade has implications for inflammation and immune cell activation.

Furthermore, CD74 plays a crucial role in B-cell development, particularly in the maturation of follicular B-cells and accumulation of marginal zone B-cells . CD74 also interacts with chemokine receptors CXCR2 and CXCR4, suggesting its involvement in chemotaxis and cell migration . Recent studies have demonstrated that CD74 can regulate chemo-attractant migration of macrophages and dendritic cells, expanding our understanding of its functional repertoire beyond antigen presentation .

How can anti-CD74 antibodies be utilized as biomarkers for spondyloarthritis?

Recent studies have investigated the potential of anti-CD74 antibodies as diagnostic biomarkers for spondyloarthritis, addressing an unmet need for reliable biomarkers in this field. A systematic review and meta-analysis of 9 studies demonstrated that both anti-CD74 IgG and IgA antibodies were significantly elevated in spondyloarthritis patients compared to controls . The standardized mean difference (SMD) was 0.88 (95% CI = 0.55 to 1.21) for IgG and 0.98 (95% CI = 0.68 to 1.28) for IgA antibodies .

What is the therapeutic potential of CD74-targeting antibodies in B-cell malignancies?

CD74-targeting antibodies show considerable promise for therapeutic applications in B-cell malignancies due to the high expression of CD74 in these cancers. Milatuzumab, a humanized monoclonal antibody targeting CD74, has been investigated for its effects on B-cell function and potential therapeutic applications . This antibody has demonstrated the ability to influence B-cell proliferation, chemotactic migration, and adhesion molecule expression, making it a candidate for treating B-cell disorders .

More recently, STRO-001, a site-specific antibody-drug conjugate (ADC) targeting CD74, has shown efficacy in xenograft models of B-cell non-Hodgkin lymphoma . The rationale for developing STRO-001 is supported by the near-ubiquitous expression of CD74 in DLBCL, FL, and MCL tissue microarrays, with CD74 expression detected in 88% of DLBCL and MCL cell lines tested . The high prevalence of CD74 expression in these malignancies, coupled with its limited expression in certain normal tissues, makes it an attractive target for ADC therapy.

How does milatuzumab affect B-cell function beyond direct cytotoxicity?

Milatuzumab, a humanized anti-CD74 monoclonal antibody, affects B-cell function through multiple mechanisms beyond direct cytotoxicity. Research has shown that milatuzumab can influence B-cell proliferation, chemotactic migration, and the expression of adhesion molecules . These effects are particularly significant because they may contribute to the therapeutic efficacy of milatuzumab in various B-cell disorders.

The specificity of milatuzumab for CD74 has been rigorously validated. Flow cytometric analyses have demonstrated that milatuzumab does not bind to T cells (MFI of 9.6 ± 1.3) but shows substantial binding to monocytes (MFI of 304 ± 70) and B cells (MFI of 704 ± 175) . Competition experiments with unconjugated milatuzumab confirmed the specificity of this binding, as it prevented binding of conjugated milatuzumab to B cells . This selective binding profile enables milatuzumab to target B cells while sparing T cells, potentially reducing off-target effects in therapeutic applications.

What are the optimal protocols for detecting CD74 expression by flow cytometry?

For optimal detection of CD74 expression by flow cytometry, researchers should consider several critical methodological aspects. First, appropriate antibody selection is crucial. When analyzing surface expression, researchers should ensure that the selected anti-CD74 antibody recognizes an extracellular epitope, as some antibodies, such as the VIC-Y1 monoclonal antibody, bind to cytoplasmic regions and cannot detect surface expression .

A validated protocol for CD74 detection by flow cytometry involves staining peripheral blood mononuclear cells (PBMCs) with fluorescently labeled anti-CD74 antibodies in conjunction with markers to identify specific cell populations. For example, CD19, CD3, and CD14 can be used to identify B cells, T cells, and monocytes, respectively . Additionally, CD27 can be included to distinguish between naïve and memory B cells . To exclude dead cells from analysis, DAPI (4,6 diamidino-2-phenylindole) should be added immediately before cytometric analysis .

For quantitative analysis, geometric mean fluorescence intensity (MFI) provides a reliable measure of CD74 expression levels. When comparing expression across different cell types or conditions, it is recommended to calculate the MFI ratio of the CD74 antibody over an appropriate isotype control . This approach controls for background fluorescence and allows for more accurate comparisons.

What considerations should be made when using CD74 antibodies for immunohistochemistry?

When using CD74 antibodies for immunohistochemistry (IHC), several technical considerations are essential for obtaining reliable and reproducible results. For formalin-fixed paraffin-embedded (FFPE) tissue sections, antigen retrieval is a critical step. Low pH antigen retrieval has been successfully used with the VIC-Y1 monoclonal antibody for staining human tonsil tissue .

When analyzing CD74 expression in tumor samples using IHC, researchers should consider using tissue microarrays for standardized comparison across multiple samples. This approach has been successfully employed to determine CD74 expression in various B-cell non-Hodgkin lymphomas, with high concordance rates . For quantitative analysis of IHC results, scoring systems based on the percentage of CD74-positive cells have been developed, with thresholds such as >70% positive cells indicating high expression .

How should researchers validate the specificity of CD74 antibodies?

Validating the specificity of CD74 antibodies is essential for ensuring reliable experimental results. One effective approach is to perform blocking experiments using unconjugated antibodies. In these experiments, cells are pre-incubated with an excess of unconjugated antibody before staining with the conjugated version of the same antibody or another antibody targeting the same epitope . A reduction in staining indicates that both antibodies compete for the same epitopes, confirming specificity.

Another validation method involves comparing staining patterns across different cell populations with known CD74 expression levels. For instance, T cells typically do not express CD74 and can serve as negative controls, while B cells and monocytes express CD74 at different levels and can serve as positive controls . The expected staining pattern—no binding to T cells but substantial binding to monocytes and B cells—provides evidence for antibody specificity .

For antibodies intended for use in flow cytometry, comparing the staining pattern of commercial anti-CD74 antibodies with the antibody being validated can provide additional confirmation of specificity. When analyzing new sample types or experimental conditions, isotype controls should always be included to account for non-specific binding .

How should variations in CD74 expression across different cell types be interpreted?

Interpreting variations in CD74 expression across different cell types requires careful consideration of both biological and technical factors. Biologically, CD74 expression levels correlate with the antigen-presenting function of cells. B cells, which are professional antigen-presenting cells, express high levels of CD74 (MFI of 44.3 ± 13.6 with commercial antibody), while monocytes express intermediate levels (MFI of 23.7 ± 7.1), and T cells, which do not typically present antigens via MHC class II, show negligible expression (MFI of 2.9 ± 0.5) .

Even within B-cell populations, CD74 expression varies significantly. Memory B cells (CD27+) consistently show higher CD74 expression compared to naïve B cells (CD27-) . This pattern mirrors the expression of CD44, a co-receptor of CD74, suggesting coordinated regulation of these molecules . These expression differences likely reflect the distinct functional capabilities of these B-cell subsets, with memory B cells possessing enhanced antigen-presenting capabilities.

In malignant contexts, CD74 expression patterns can provide insights into disease biology. In B-cell non-Hodgkin lymphomas, CD74 copy numbers vary widely across cell lines, from high levels (51,000-77,000 copies) to below detection limits . These variations may reflect differences in tumor biology or cell of origin and could have implications for the efficacy of CD74-targeted therapies.

What factors can affect the reliability of CD74 expression analysis in clinical samples?

Multiple factors can influence the reliability of CD74 expression analysis in clinical samples, presenting challenges for researchers and clinicians. Pre-analytical variables, including sample collection, storage, and processing methods, can significantly impact CD74 detection. Fresh samples typically yield more reliable results than frozen or fixed tissues, particularly for surface expression analysis.

Technical variables in the detection method also play a crucial role. For flow cytometry, factors such as antibody clone, fluorochrome brightness, instrument settings, and gating strategies can all affect the measured CD74 expression levels. When analyzing tissue samples by immunohistochemistry, variables including fixation method, antigen retrieval protocol, detection system, and scoring criteria can introduce variability .